Allogene Therapeutics, Inc.

NASDAQ:ALLO

Biotechnology

Healthcare
$0.70 +1.02%

+$0.02 today

Market cap
$241.11M
Beta
0.46
P/E (TTM)
-2.7
EPS (TTM)
-$0.72
52W Low $0.98High $4.46

Volume 10.55M

Average 10.19M

ALLO Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Allogene Therapeutics, Inc.NASDAQ: ALLO

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity falls 27.6% from a year ago

Total equity stood at $278.88M at the end of Q1 FY2026, down 27.6% from a year earlier and down 4.7% from the prior quarter. Over 3 fiscal years it compounded at -24.0% a year.

Context

  • Total equity amounted to 70.4% of total assets at the end of Q1 FY2026, down 5.4 pp from a year earlier.
  • Total equity increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps falling in the next quarterly balance sheet after a -27.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$278.88M-4.7% QoQ
Last fiscal yearDec 2025
$292.54M-30.7% YoY
Year agoMar 2025
$385.39M-27.6% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-27.6%——
1 year-30.7%——
3-year CAGR-24.0%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
292.54M USD
Year-over-year change
-30.7%
4-year CAGR
-25.0%

Total Equity vs competitors

How ALLO compares with its peers on the latest reported figures

  • ALLO's Mar 2026 total equity of $278.88M is the highest of the 9 companies compared; the peer median is $89.06M.
  • Its year-over-year change of -27.6% is the 4th highest of 9, against a peer median of -43.1%.
  • Total equity amounts to 70.4% of total assets for ALLO, versus a peer median of 58.0%.
ALLO Competitors Peer median
Total Equity for ALLO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ALLOAllogene Therapeutics, Inc.Mar 2026$278.88M -27.6%-24.0%70.4%
IPSCCentury Therapeutics, Inc.Mar 2026$264.74M +10.1%-19.3%81.1%
FATEFate Therapeutics, Inc.Mar 2026$179.71M -37.7%-24.6%63.1%
AUTLAutolus Therapeutics plcMar 2026$108.83M -70.7%-15.8%20.6%
CRBUCaribou Biosciences, Inc.Mar 2026$102.02M -53.0%-25.9%68.5%
DTILPrecision BioSciences, Inc.Mar 2026$76.1M +54.2%+15.1%52.9%
CLLSCellectis S.A.Mar 2026$59.92M -48.4%-15.5%20.7%
ATRAAtara Biotherapeutics, Inc.Mar 2026-$37.31M +32.2%—186.6%
CELUCelularity Inc.Dec 2025-$38.06M -530.7%—35.5%
Peer median (excluding ALLO) $89.06M-43.1%-17.6%58.0%

Competitors are the stored peer set for ALLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents173.31M61.9M83.16M75.22M51.69M
Short-term Investments283.99M455.42M365.54M217.26M198.52M
Net Receivables001.7M1.9M1.5M
Inventory00000
Other Current Assets011.5M09.01M6.04M
Total Current Assets471.32M528.82M459.12M303.39M257.75M
Property, Plant & Equipment (Net)181.02M196.43M163.18M131.26M112.73M
Goodwill00000
Intangible Assets00000
Long-term Investments382.38M76.47M3.65M80.67M8.04M
Tax Assets00000
Other Non-current Assets16.11M19.86M16.9M33.39M37.39M
Total Non-current Assets579.51M292.76M183.72M245.32M158.16M
Total Assets1.05B821.58M642.84M548.71M415.91M
Account Payables10.26M13.89M5.9M5.39M4.27M
Short-term Debt00000
Tax Payables00000
Deferred Revenue156K95K86K00
Other Current Liabilities16.13M17.94M11.66M12.15M10.24M
Total Current Liabilities47.91M53.73M37.08M35.52M32.51M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities7.79M5.85M5.18M7.76M15.8M
Total Non-current Liabilities77.72M100.97M93.53M91.01M90.85M
Total Liabilities125.63M154.7M130.6M126.53M123.36M
Common Stock142K144K169K212K229K
Retained Earnings(894.55M)(1.23B)(1.56B)(1.82B)(2.01B)
Accumulated OCI(2.57M)(9.93M)(955K)(89K)269K
Other Stockholders Equity00000
Minority Interest00000
Total Equity925.2M666.88M512.23M422.18M292.54M
Total Debt73.13M101.12M95.12M90.76M83.25M
Net Debt(100.19M)39.22M11.97M15.54M31.57M

Allogene Therapeutics, Inc.

NASDAQ:ALLO

Intrinsic Alpha fair value

Locked

Current Price

$0.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.